Codon Optimization and Construction of Recombinant Plasmid for SARS-CoV-2 RBD Protein on E. coli BL21(DE3)
Optimasi Kodon dan Konstruksi Plasmid Rekombinan Protein RBD SARS-CoV-2 pada E. coli BL21(DE3)
Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted over 7 million deaths worldwide. Comprehensive strategies are necessary to combat this pandemic, especially vaccination to mitigate further infection and devastation. The development of vaccines hinges upon the utilization of immunogenic proteins from the SARS-CoV-2 virus, with particular emphasis on the receptor-binding domain (RBD) located within the spike glycoprotein’s subunit 1. This protein plays a key role in the virus’s interaction with host cells via ACE2 receptor to infect the host along with the subunit 2 to mediate the cell membrane fusion. While there are multiple vaccines in existence, there is a requirement to create more affordable and accessible vaccine alternatives, especially in developing countries. Potential improvements can be implemented within the vaccine development paradigm, including the exploration of recombinant protein-based vaccines as a viable alternative. In the present study, we optimized the RBD gene sequence as the critical step to construct a recombinant plasmid for heterologous prokaryotic protein expression in Escherichia coli BL21(DE3). The optimized codon then inserted into the plasmid vector pET-15b and constructed a recombinant plasmid for transformation into cell host by heat-shock method. The study was evaluated and validated through colony PCR, plasmid isolation, and sequencing. These findings offering a foundational basis for further research in the expression and purification of RBD SARS-CoV-2 protein in E. coli BL21(DE3) as a candidate for subunit recombinant protein vaccine or diagnostic tool in COVID-19 research.
Copyright (c) 2024 Elly Widyarni Eka Purnamasari, Dini Wahyu Kartika Sari, Tenri Ashari Wanahari, Khairun Nissa, Asmarani Kusumawati
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY), that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).